Text Size
340 studies found for:    Open Studies | Interventional Studies | melanoma

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Not yet recruiting Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib
Conditions: Metastatic Melanoma;   Melanoma;   BRAF-mutated Metastatic Melanoma;   V600EBRAF-mutated Metastatic Melanoma
Intervention: Drug: Vemurafenib, Decitabine
22 Recruiting Adoptive T Cell Therapy for Metastatic Ocular Melanoma
Conditions: Metastatic Ocular Melanoma;   Metastatic Uveal Melanoma
Interventions: Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Tumor Infiltrating Lymphocytes
23 Recruiting SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Conditions: Mucosal Melanoma;   Acral/Lentiginous Melanoma
Intervention: Drug: SU011248
24 Recruiting Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Cutaneous Melanoma
Interventions: Drug: Interferon alpha;   Drug: KW2871;   Drug: interferon alpha
25 Not yet recruiting Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma
Interventions: Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC);   Biological: Autologous PBMCs in GM-CSF (MC)
26 Recruiting mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma
Conditions: Malignant Melanoma Stage III;   Malignant Melanoma Stage IV
Intervention: Biological: Dendritic cell therapy
27 Recruiting IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
Conditions: Malignant Melanoma Stage III;   Malignant Melanoma Stage IV
Intervention: Biological: IL15-DC Vaccine
28 Not yet recruiting Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Melanoma That is Metastatic or That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate;   Drug: vemurafenib;   Other: laboratory biomarker analysis
29 Recruiting Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Solid Tumor
Intervention: Drug: MLN2480
30 Recruiting Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Conditions: Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
31 Recruiting Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Drug: cyclophosphamide;   Procedure: biopsy;   Biological: aldesleukin;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Biological: therapeutic allogeneic cytotoxic T lymphocytes
32 Recruiting Vaccine Therapy With or Without Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: NA17.A2 peptide vaccine;   Biological: recombinant MAGE-3.1 antigen;   Biological: recombinant interleukin-12;   Biological: MART-1 antigen;   Other: laboratory biomarker analysis
33 Recruiting Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: CD40 agonist monoclonal antibody CP-870,893;   Biological: tremelimumab;   Other: laboratory biomarker analysis
34 Recruiting Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Conditions: Metastatic Intraocular Melanoma;   Recurrent Intraocular Melanoma
Interventions: Drug: vorinostat;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: diagnostic laboratory biomarker analysis
35 Recruiting Bevacizumab vs Dacarbazine in Metastatic Melanoma
Conditions: Metastatic Malignant Melanoma;   Unresectable Malignant Melanoma
Interventions: Drug: Bevacizumab;   Drug: Propranolol;   Drug: Enalapril;   Drug: Dacarbazine
36 Recruiting Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Intervention: Biological: BMS-936558 (Anti-PD-1)
37 Recruiting Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: temozolomide;   Other: flow cytometry;   Other: staining method;   Procedure: biopsy;   Other: laboratory biomarker analysis
38 Unknown † A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread
Conditions: Mucosal Lentiginous Melanoma;   Acral Lentiginous Malignant Melanoma
Intervention: Drug: nilotinib
39 Not yet recruiting Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab Therapy
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Procedure: scintigraphy;   Other: laboratory biomarker analysis;   Biological: technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2
40 Recruiting Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
Conditions: Recurrent Melanoma;   Stage IV Melanoma;   Tumors Metastatic to Brain
Interventions: Drug: Ipilimumab;   Radiation: Whole-Brain Radiation Therapy (WBRT);   Radiation: Stereotactic Radiosurgery (SRS)
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years